These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18264876)

  • 21. An exploration of Latino smokers and the use of pharmaceutical aids.
    Levinson AH; Borrayo EA; Espinoza P; Flores ET; Pérez-Stable EJ
    Am J Prev Med; 2006 Aug; 31(2):167-71. PubMed ID: 16829334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoking cessation treatment in a real-life setting: the Greek experience.
    Rovina N; Nikoloutsou I; Dima E; Michailidou M; Roussos C; Gratziou C
    Ther Adv Respir Dis; 2007 Dec; 1(2):93-104. PubMed ID: 19124351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial uptake and evidence of safe prescribing practice with Buproprion (Zyban).
    Williams D; Bennett K; Heery A; Feely J
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):411-5. PubMed ID: 15170772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescribing trends for nicotine replacement therapy in primary care.
    Tilson L; Bennett K; Barry M
    Ir Med J; 2004 Oct; 97(9):270-3. PubMed ID: 15568584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
    Nielsen K; Fiore MC
    Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
    Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
    Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost effectiveness of pharmacotherapies for smoking cessation: necessary but not sufficient?
    Shanahan M; Doran C; Gates J; Shakeshaft A; Mattick RP
    Appl Health Econ Health Policy; 2003; 2(2):76-8. PubMed ID: 14619277
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
    Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
    Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of the introduction of smoke-free legislation on prescribing of stop-smoking medications in England.
    Szatkowski L; Coleman T; McNeill A; Lewis S
    Addiction; 2011 Oct; 106(10):1827-34. PubMed ID: 21561500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program.
    Alberg AJ; Stashefsky Margalit R; Burke A; Rasch KA; Stewart N; Kline JA; Ernst PA; Avey A; Hoffman SC
    Addict Behav; 2004 Dec; 29(9):1763-78. PubMed ID: 15530720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of bupropion hydrochloride for smoking cessation therapy.
    Nichols MR
    Clin Excell Nurse Pract; 1999 Nov; 3(6):317-22. PubMed ID: 10865568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breaking the ties of nicotine dependence.
    Bennett SM; Andrews JO; Heath JH
    Nurse Pract; 2007 Nov; 32(11):36-45; quiz 45-6. PubMed ID: 18075457
    [No Abstract]   [Full Text] [Related]  

  • 34. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
    Bolin K; Lindgren B; Willers S
    Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success?
    Gilpin EA; Messer K; Pierce JP
    Nicotine Tob Res; 2006 Oct; 8(5):661-9. PubMed ID: 17008193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
    Woolacott NF; Jones L; Forbes CA; Mather LC; Sowden AJ; Song FJ; Raftery JP; Aveyard PN; Hyde CJ; Barton PM
    Health Technol Assess; 2002; 6(16):1-245. PubMed ID: 12269277
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of pharmacological tobacco cessation relapse rates.
    McMurry TB
    J Community Health Nurs; 2006; 23(1):15-28. PubMed ID: 16445361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity in preferences for smoking cessation.
    Paterson RW; Boyle KJ; Parmeter CF; Neumann JE; De Civita P
    Health Econ; 2008 Dec; 17(12):1363-77. PubMed ID: 18189227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation.
    Becker KM; Rose JE; Albino AP
    Nicotine Tob Res; 2008 Jul; 10(7):1139-48. PubMed ID: 18629723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.